Register for updates

 
 

Medicine & Health
RSS Feed
A Biological Approach to Precision Medicine Targets Endless Number of Diseases
Thursday, February 01, 2018 9:00:00 AM

Self-assembling platform effectively delivers inhibitory RNA molecules to targeted cell populations, TAU researchers say

The biological complexity of cancer and other diseases demands a more formidable arsenal of therapies than currently available. Most therapeutic approaches ignore the dynamic molecular network of genes, targeting instead only very few selected disease-related genes.

A new Tel Aviv University study published in Nature Nanotechnology proposes a novel approach to manipulate genes using a self-assembling platform that delivers nucleic acids, such as small interfering RNAs (siRNAs), to distinct cell subsets. While current practices of precision medicine target a single cellular receptor, the new modular platform offers a robust biological approach — and may hold the key to the future of personalized medicine.

"The siRNA delivery targeted carriers constructed today hone in on specific cells and require chemical conjugation of the targeting agent," says Prof. Dan Peer of the Laboratory of Precision Nanomedicine at TAU's School of Molecular Cell Biology and Biotechnology, who led the research. "The new platform is based on biological affinity, a self-assembling approach that can be translated to target an endless number of diseases and conditions."

Research for the study was conducted by first co-authors Dr. Ranit Kedmi and Nuphar Veiga and colleagues at Prof. Peer's TAU Laboratory, in collaboration with Prof. Itai Benhar of TAU’s School of Molecular Cell Biology and Biotechnology, Dr. Michael Harlev of TAU's Veterinary Service Center, Dr. Mark Belkhe of Integrated DNA Technologies (IDT) and Prof. Judy Lieberman of Boston Chidren's Hospital and Harvard Medical School.

Locating the "linker"

According to Prof. Peer, the new platform "removes many of the hurdles" plaguing precision medicine today. At the heart of the delivery platform is the "linker," a lipoprotein that binds to the antibody constant region. Since all antibodies of the same family share a common region, a simple alteration of the antibody results in a novel delivery carrier that adjusts to the target receptor of choice.

"Because its construction relies on affinity interactions, there's no need to introduce chemical conjugation optimizations for the method to function," says Prof. Peer. "Linkers are stuck in the nanoparticle membrane and bind to a fixed region of any antibody of the same isotype. This affords safe passage to a theoretically unlimited selection of carriers targeting distinct cell surface receptors."

"We believe this modular delivery platform serves as a milestone that renders precision medicine truly feasible," says Ms. Veiga. "The challenge has been how to direct certain therapies designed to manipulate genes of interest in specific cells without developing a specific drug carrier for each specific cell type. It would be very costly and impractical to develop millions of different drugs to treat every specific cell type and specific gene. Rather, the focus should be on developing a nucleic acid-based tool to manipulate gene expression through a simple, constant exchange."

Fast results

For the research, the scientists used the platform to target colon macrophages in order to reduce inflammatory symptoms caused by Inflammatory Bowel Disease (IBD) in mouse models. "One can easily obtain fast results using these targeted carriers," says Prof. Peer. "The mice exhibited far less inflammation, which suggests the possibility of promising new IBD therapeutic opportunities."

The researchers also affected mouse models with Mantle Cell Lymphoma, using the new platform to target cancer cells, induce cell death and dramatically improve overall survival.

"Our research supports the development of targeted nucleic acid delivery platforms for therapeutics for autoimmune diseases and cancer," says Prof. Peer. "Our delivery platform can be adjusted for each patient to target a potentially endless number of receptors.

"It's flexible enough to be easily customized to target any cell subset and to knock down any gene of choice. We think it has tremendous research and therapeutic potential."

The researchers are currently interested in advancing a proof-of-concept in humans.

Funding for the research was provided by the Dotan Center for Hemato-oncology at Tel Aviv University, The Kenneth Rainin Foundation, The Leona M. and Harry B. Helmsley Nanotechnology Research Fund and the European Research Council.




Latest News

The Steinhardt Museum of Natural History at TAU to Open July 2018

New museum displays thousands of items that tell the story of biodiversity in Israel and the Middle East.

Modern Laser Science Brightened by 2,300-Year-Old Technology

Archimedes' screw inspires TAU researchers to devise a novel particle-trapping laser beam.

Neuronal Activity Sheds Light on the Origin of Consciousness

Electrodes in patients with epilepsy register neuronal activity underlying emergence of conscious experience, TAU researchers say.

Philadelphia Orchestra Performs with TAU Students, Israel Philharmonic in Packed Concert

Orchestra's trip to Israel is the third visit to the country by a major U.S. symphony orchestra.

TAU Student Film Wows at Cannes Film Festival

Rubber Dolphin written and directed by Steve Tisch School of Film and Television graduate.

Changes to Specific MicroRNA Involved in Development of Lou Gehrig's Disease

Mechanism involving specific microRNA and muscle molecules plays role in amyotrophic lateral sclerosis, TAU researchers say.

Why Diversity Programs Promoting Women and Minorities in Management Fail

Current tools that "force-feed" diversity engender bias and rebellion, TAU and Harvard University researchers say.

Moderate Decline in Violent Attacks Against Jews, But Attacks Are Becoming More Brutal

European Jews harbor increasingly "grave concerns for their security," annual TAU Kantor Center study reports.

TAU Announces Early-Stage Venture Fund to Invest in Student Innovation

TAU Ventures similar to funds at universities such as MIT, UC Berkeley and Stanford.

How Advanced Nanotechnology Can Improve Cancer Care

TAU, Harvard University researchers discuss untapped potential of targeted nanocarriers to revolutionize cancer therapy.

contentSecondary
c

© 2018 American Friends of Tel Aviv University
39 Broadway, Suite 1510 | New York, NY 10006 | 212.742.9070 | info@aftau.org
Privacy policy | Tel Aviv University